Buy PT-141 Peptide Finland
PT-141, or Bremelanotide, is a synthetic peptide that stimulates melanocortin receptors in the brain to enhance sexual desire and function in both men and women. By targeting the brain’s sexual response circuits, it shows potential as a treatment for sexual dysfunction or low libido.
Shop our Full Range of PT-141 Peptides Finland
-
Sale!
PT-141 Oxytocin Nasal Stack
£45.08 – £81.17 This product has multiple variants. The options may be chosen on the product page -
Sale!
PT-141 Oxytocin Peptide Stack
£26.89 – £35.87 This product has multiple variants. The options may be chosen on the product page -
Sale!
Kisspeptin PT-141 Nasal Stack
£51.65 – £94.30 This product has multiple variants. The options may be chosen on the product page -
Sale!
PT-141 Kisspeptin Peptide Stack
£37.25 – £46.23 This product has multiple variants. The options may be chosen on the product page -
New Reduced Price
New Reduced Price
New Reduced Price
New Reduced Price
New Reduced Price
PT-141 10mg Pre Mixed Pen
£24.03 – £64.88 This product has multiple variants. The options may be chosen on the product page -
New Reduced Price
New Reduced Price
New Reduced Price
PT-141 (Bremelanotide) Nasal Spray
£29.45 – £97.02 This product has multiple variants. The options may be chosen on the product page -
New Reduced Price
New Reduced Price
PT-141 (Bremelanotide)
£21.45 – £38.61 This product has multiple variants. The options may be chosen on the product page
PT-141 Mechanism Of Action
PT-141, or Bremelanotide, is a synthetic peptide being studied for its ability to enhance sexual performance. It has shown potential in improving sexual function for both men and women, particularly those with erectile dysfunction (ED) or hypoactive sexual desire disorder (HSDD).
This innovative solution is administered via subcutaneous injection or nasal spray and is still undergoing research to evaluate its effectiveness and safety in clinical use.
It works by interacting with melanocortin receptors (MCRs), especially the melanocortin-4 receptor (MC4R) in the central nervous system. This interaction influences the brain’s neural pathways that regulate sexual desire and arousal. Unlike traditional treatments for sexual dysfunction that improve blood flow through the vascular system, PT-141 targets neurological signals directly, focusing on the brain’s role in sexual response.
When administered, PT-141 activates MC4R, which is connected to the hypothalamus, a key area in the brain responsible for behavior and hormone regulation. This activation stimulates the hypothalamic-pituitary-gonadal (HPG) axis, leading to the release of neurotransmitters like dopamine, which are crucial for sexual motivation and arousal. These processes help improve sexual desire and function.
Because PT-141 works on the central mechanisms of sexual desire, it offers a unique approach to addressing sexual dysfunction. Its focus on brain signals rather than blood flow means it avoids the cardiovascular side effects often associated with other treatments. This makes PT-141 a promising option for treating conditions such as HSDD and a potentially groundbreaking development in sexual health.
Source: PubChem
Structure of PT-141
Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.2 g/mol
PubChem CID: 9941379
What Are The Research Benefits of PT-141?
Novel Mode of Action: PT-141’s mechanism of targeting the central nervous system rather than the vascular system offers a new avenue for understanding sexual arousal and desire, making it a pioneering subject in sexual dysfunction research.
Targeted Neurological Effects: By modulating melanocortin receptors, especially MC4R, PT-141 enables Finland researchers to explore the complex neural pathways involved in sexual response, potentially leading to breakthroughs in neurobiological research.
Reduced Cardiovascular Risks: Due to its central nervous system activity, PT-141 Finland potentially offers a safer profile compared to conventional treatments for sexual dysfunction that function via the vascular system. This reduction in cardiovascular involvement may lessen the risk of adverse events, such as haemorrhage, associated with increased blood flow or vascular stress.
Potential in Infection Research: Emerging Finland studies suggest the peptide may have promising applications beyond sexual dysfunction, particularly in infection research. As a melanocortin receptor agonist, PT-141 can influence immune system modulation.
Researchers are evaluating its potential to enhance immune responses and combat infections. By activating melanocortin receptors, Bremelanotide might help regulate inflammation and improve the body’s ability to fight pathogens, offering a novel approach to infection management.
Exploring PT-141’s mechanisms further could lead to innovative therapies that address sexual dysfunction and bolster the immune system, marking an exciting intersection of neuroendocrinology and immunology.
Exploratory Research on Haemorrhage Risks: Researchers can utilise PT-141 to investigate its effects on sexual arousal without the heightened risk of haemorrhage. This is particularly significant for populations that may be predisposed to vascular complications, allowing for safer therapeutic exploration and potential applications.
Potential in Oncology Research: Emerging studies suggest that PT-141 may have applications beyond sexual dysfunction, including potential implications in oncology research. Its unique interaction with melanocortin receptors, particularly MC4R, opens new possibilities for exploring how these pathways may influence cancer cell behaviour and proliferation. By delving into PT-141’s effects on cellular mechanisms involved in tumour growth and metastasis, researchers could uncover novel therapeutic strategies for cancer treatment.
The versatility and multifaceted mode of action of PT-141 thus make it an intriguing subject not only in sexual health but also in broader medical research domains, including oncology. This could pave the way for innovative approaches to cancer therapy that target specific receptor pathways, providing a new direction for future research initiatives.
Broad Therapeutic Potential: PT-141’s ability to directly influence sexual desire and arousal positions it as a versatile compound for investigating and potentially treating conditions like hypoactive sexual desire disorder (HSDD) in both men and women.
Enhanced Bioavailability: Research formulations of PT-141 Finland are optimised for maximum absorption and utilisation within the body, providing more reliable and consistent results in experimental settings.
Comprehensive Experimental Applications: PT-141 supports a wide range of research applications, from understanding fundamental sexual behaviour to developing potential therapeutic agents for sexual health disorders.
Supporting Advanced Studies: With its defined mechanism and targeted effects, PT-141 lays the groundwork for more advanced and specialised studies into the neurological and endocrinological aspects of sexual function.
Buy PT-141 for research online today!
Kisspeptin and PT-141 Peptide Stack For Sale
Buy PT-141 Kisspeptin Peptide Stack Finland and discover the synergistic effects of combining these two peptides. They each target different aspects of sexual function and reproductive health. PT-141, a melanocortin receptor agonist, enhances sexual arousal by acting on the central nervous system.
In contrast, Kisspeptin is essential for the regulation of puberty and reproductive hormone release, making it pivotal for fertility studies.
This combination can provide a comprehensive approach to addressing sexual dysfunction and studying reproductive processes, offering unique advantages for research into complex hormonal pathways and sexual health dynamics.
Buy PT-141 and Kisspeptin Stack online today!
Buy PT-141 Peptide Nasal Spray
Buy PT-141 nasal spray, a convenient and effective method for researching this peptide for sexual dysfunction. The spray has pharmacokinetic properties which allow rapid absorption into the bloodstream, enabling quicker action compared to other methods. Available in 15ml and 30ml bottles, it offers a user-friendly option that eliminates injections, enhancing compliance and ease of use.
The popularity of this nasal spray among researchers highlights its potential beyond sexual dysfunction, including neuroendocrine and central nervous system studies. As research uncovers its full range of benefits, PT-141 nasal spray remains a versatile tool in peptide research.
Buy PT-141 nasal spray online from Direct Peptides Finland.
Frequently Asked Questions (FAQs) about PT-141
What is the regulatory status of PT-141?
Clinical trials have recieved regulatory approval in various regions to buy PT-141 for treating HSDD in premenopausal women. Approval includes the Food and Drug Administration (FDA) in the United States, the Therapeutic Goods Administration (TGA) in Australia, and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Continued research and development are expanding its potential applications and approval statuses globally.
Can PT-141 be used alongside other medications?
Bremelanotide can interact with other medications, so researchers must consult a healthcare provider before combining it with other treatments. This ensures the safe and effective use of PT-141, preventing adverse interactions that could affect research outcomes or participant health. Finland Researchers should perform detailed pharmacological assessments and follow professional guidance to maintain study integrity and safety.
How quickly does PT-141 work?
The effects of Bremelanotide can typically enhance erectile function within 30 minutes to an hour after administration. The duration of its impact can vary, but it generally lasts several hours, providing ample time for sexual activity.
Are there any side effects associated with PT-141?
Like any medication, Bremelanotide can cause potential side effects, with nausea, headache, irritation at the injection site, and flushing being the most commonly reported. However, it presents fewer cardiovascular risks, making it a potentially safer alternative to other sexual dysfunction therapies.
Are there any off-label uses for PT-141?
Research is ongoing into potential off-label uses of PT-141, including its role in infection research and oncology. Although promising, these applications are still under study, and PT-141 should only be used as prescribed by a healthcare professional.
What makes PT-141 different from other treatments for sexual dysfunction?
Unlike other treatments that primarily act on the vascular system to achieve their effects, Bremelanotide targets the central nervous system. This unique mechanism may offer better efficacy for some individuals and a reduced risk of cardiovascular side effects.
Where is the best place to buy PT-141?
The best place to buy PT-141 with assured quality and high purity is from Direct Peptides Finland. We offer PT-141 peptides with a guaranteed purity of 99%, making us the ideal choice for researchers seeking reliable and effective solutions.
Summary of Research Applications
- Treatment of HSDD in premenopausal women.
- Central Nervous System Activation targeting melanocortin receptors, particularly MC4R, for its effects.
- Research indicates potential benefits for male ED patients with similar erectile response issues.
- Reduced cardiovascular side effects compared to other sexual dysfunction therapies.
- Neuroendocrinological Studies: Supports advanced research into the neurological and endocrinological aspects of sexual function.
- Ongoing research into broader applications, including infection research and oncology.
PT-141 Peptide Quality Assured
At Direct Peptides Finland, we redefine excellence in peptide solutions, offering PT-141 peptides with 99% purity guaranteed. Our meticulous synthesis process ensures each batch exceeds industry standards for quality and efficacy, embodying our commitment to precision.
Our dedication to purity not only reinforces our reputation for outstanding quality but also enhances the therapeutic potential of PT-141. This ensures our clients receive a product tailored to their research needs with unmatched reliability, supporting advanced investigations and innovative applications.
When you buy PT-141 from us, you receive a top-tier compound designed to enhance your research and deliver valuable insights.
View the High-Performance Liquid Chromatography HPLC Certificate here.
References For Further Reading
[1] H.Wessells, V.J.Hruby, J.Hackett, et al (2003) Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors – Neuroscience, 2003;118(3):755-62
[2] R.C.Rosen, L.E.Diamond, D C Earle, et al (2004) Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra – International Journal of Impotence Research, 2004 Apr;16(2):135-42.
[3] M.R.Safarinejad and S.Y.Hosseini (2008) Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study – The Journal of Urology, 2008 Mar;179(3):1066-71.
[4] A.S.Rössler, J.G.Pfaus, H.K.Kia, et al (2006) The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat – Pharmacology, Biochemistry, and Behaviour, Volume 85, Issue 3, November 2006, Pages 514-521.
[5] P.B.Molinoff, A.M.Shadiack, D.Earle, L.E.Diamond, and C.Y.Quon (2006) PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction – Annals of the New York Academy of Sciences, Volume 994, Issue 1, The Melanocortin System, June 2003, Pages 96-102.
[6] A.H.Clayton, S.E.Althof, S.Kingsberg, et al (2016) Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial – Womens Health (London), 2016 Jun; 12(3): 325–337.
[7] M.K.Miller, J.R.Smith, J.J.Norman, et al (2018) Expert opinion on existing and developing drugs to treat female sexual dysfunction – Expert Opinion on Emerging Drugs, 2018 Sep;23(3):223-230.
[8] C.Spana, R.Jordan, and S.Fischkoff (2022) Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials – Diabetes Obesity and Metabolism, 2022 Jun;24(6):1084-1093.
[9] M.Sandrock, A.Schulz, C.Merkwitz, et al (2009) Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice
– Reproductive Biology and Endocrinology, 2009; 7: 24.
[10] L.Feller, R.A.G.Khammissa, B.Kramer, et al (2016) Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face – Head Face Medicine, 2016 Feb 5:12:11
[11] V.Maresca, E.Flori, and M.Picardo (2015) Skin phototype: a new perspective – Pigment Cell and Melanoma Research, 2015 Jul;28(4):378-89.
Why Choose Direct Peptides Finland?
Buy PT-141 today and experience unmatched quality with Finland Direct Peptides, your premier source for Bremelanotide peptides. Setting us apart is our unique array of PT-141 formulations, including peptide vials available in 10mg and a kit with bacteriostatic water and syringes. We also offer peptide nasal sprays available in 15ml and 30ml spray bottles, pre-mixed peptide pens, and even peptide stacks. Catering to varied research needs, we ensure that Finland researchers have access to the precise formulation required for their specific projects.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Finland Direct Peptides website: https://finland.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
Related Posts
Peptide Stack PT-141 and Kisspeptin Potential to Help With Sexual Dysfunction
Addressing sexual dysfunctions, and offering insights from both hormonal and neurological perspectives.
PT-141 For Women's Libido
This article explores PT141 as a possible treatment to enhance libido in premenopausal women by addressing both physical and psychological aspects of sexual desire. It highlights patient reported improvements, a solid safety record, and few side effects.
What Is PT-141?
A brief look at PT-141 in comparison to other medications in the market such as Viagra. It also discusses clinical trials with nasal sprays which have shown promise. With more research, it could gain FDA approval to treat low libido and sexual dysfunction in men and women.
